PLD6

Across TCGA pan-cancer cohorts, PLD6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLD6 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PLD6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLD6 expression acts as an unfavorable survival marker.

LUSC, KIRP, and ESCA are the cancer types where PLD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	36	view →
KIRP	OS	Median	All	0.148	0.904	<.001	30	view →
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
BRCA	OS	Median	III,IV	0.165	0.833	<.001	14	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLD6–LUSC (DFS)

Open the LUSC breakdown →